We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
LOGC | ContextLogic Inc | 5.13 | 3.06 | 147.83% | 9 |
ACIU | AC Immune SA | 3.45 | 1.14 | 49.35% | 7,872,553 |
TVGN | Tevogen Bio Holdings Inc | 1.46 | 0.4755 | 48.30% | 7,456,405 |
KITT | Nauticus Robotics Inc | 0.188 | 0.0412 | 28.07% | 15,388,409 |
FLGC | Flora Growth Corporation | 1.73 | 0.36 | 26.28% | 105 |
CCLD | CareCloud Inc | 1.59 | 0.33 | 26.19% | 2,212,991 |
AACG | ATA Creativity Global | 1.10 | 0.20 | 22.22% | 15 |
DYNT | Dynatronics Corp | 0.575 | 0.1025 | 21.69% | 228 |
INKT | MiNK Therapeutics Inc | 1.08 | 0.18 | 20.00% | 2,895,423 |
ATNF | 180 Life Sciences Corporation | 2.30 | 0.37 | 19.17% | 201 |
TARS | Tarsus Pharmaceuticals Inc | 43.69 | 6.69 | 18.08% | 116 |
Translational Study Provides Pre-Clinical Evidence to Support The Design of a Phase 1 Study of the Hemopurifier In Cancer Patients With Solid Tumors Treated With Anti-PD-1 Antibodies SAN DIEGO, May 10, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced positive results from an in vitro binding study of its Hemopurifier® in removing extracellular vesicles (EVs) from plasma. The translational study provides pre-clinical evidence to support Aethlon's planned phase 1 safety, feasibility and dose-finding clinical trials of the Hemopurifier in patients with solid tumors ...
Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, announced financial results for the first quarter ended March 31, 2024, and provided a business update.
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that HeartBeam AIMIGo™ has been selected as winner of the “Best New ECG Technology Solution” award in the 8th annual MedTech Breakthrough Awards program. The awards program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market.
Collaboration will Transition the Company from R&D to Commercialization REHOVOT, Israel, May 13, 2024 /PRNewswire/ -- Steakholder Foods Ltd. (Nasdaq: STKH), a leading innovator in alternative proteins and 3D printing technologies, announced a royalties and raw materials supply agreement with Wyler Farm Ltd., a leader in alternative protein production, whereby Wyler Farm will manufacture alternative proteins on a commercial scale using Steakholder Foods' premixes and know-how, in return for the payment of royalties from sales. The agreement is expected to generate the company's first commercial revenue, and marks Steakholder Foods' early transition from R&D to commercialization.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 62,751.43 | 1,303.43 | 2.12% | 1.23T | 3,265,851,646 |
ETH | Ethereum | 2,964.14 | 36.64 | 1.25% | 356.38B | 1,646,735,517 |
USDT | Tether USD | 0.99965 | 0.00016 | 0.02% | 97.8B | 105,992,675 |
BNB | Binance Coin | 593.84 | 0.127004 | 0.02% | 93.92B | 304,321,988 |
SOL | Solana | 145.87 | 1.57 | 1.09% | 64.43B | 854,457,633 |
STETH | stETH | 2,963.06 | 37.31 | 1.28% | 29.1B | 3,418,021 |
USDC | USD Coin | 0.99997 | -0.00001 | 0.00% | 28.07B | 453,335,683 |
XRP | Ripple | 0.5079 | 0.00836 | 1.67% | 27.63B | 253,247,556 |
TONCOIN | Wrapped TON Coin | 7.29 | 0.32142 | 4.62% | 25.51B | 431,784,884 |
DOGE | Dogecoin | 0.14415 | 0.00165 | 1.16% | 20.57B | 331,940,100 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions